(lp0
S'The New York State Common Retirement Fund Increases Position in Vanda ... Petro Global News 24 - Feb 4, 2017 Other institutional investors also recently modified their holdings of the company. UBS Asset Management Americas Inc. increased its position in shares of Vanda Pharmaceuticals by 10.9% in the second quarter. UBS Asset Management Americas Inc. now&nbsp;...'
p1
aS'Stocks: The Vanda Pharmaceuticals Inc.  Stock Rating Reaffirmed by ... Petro Global News 24 - Feb 1, 2017 A number of other research analysts also recently weighed in on VNDA. Piper Jaffray Companies set a $19.00 target price on Vanda Pharmaceuticals and gave the stock a buy rating in a report on Saturday, October 1st. Zacks Investment Research&nbsp;...'
p2
aS'Vanda Pharmaceuticals to Announce First Quarter 2017 Financial Results on May ... PR Newswire  - Apr 13, 2017 ... biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.Metropolitan Life Insurance Co. NY Has $472000 Stake in Vanda Pharmaceuticals ... - BNB Daily Vanda Pharmaceuticals Inc.  Coverage Initiated by Analysts at ... - The Cerbat Gem'
p3
aS'Vanda Pharmaceuticals Reports Fourth Quarter 2015 and Full Year 2015 Financial ... PR Newswire  - Feb 10, 2016 10, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc.  , today announced financial and operational results for the fourth quarter and full year ended December 31, 2015.'
p4
aS"State Street Corp Has $27.935 Million Stake in Vanda Pharmaceuticals Inc.  The Cerbat Gem - 5 hours ago Vanda Pharmaceuticals logo State Street Corp increased its position in Vanda Pharmaceuticals Inc.  by 27.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC.Vanda Pharmaceuticals Inc.  Earns Outperform Rating from Analysts at ... - Markets DailyVanda Pharmaceuticals'  Outperform Rating Reiterated at CIBC - Sports Perspectives"
p5
aS"Vanda Pharmaceuticals Reports Second Quarter 2016 Financial Results PR Newswire  - Jul 27, 2016 WASHINGTON, July 27, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc.  , today announced financial and operational results for the second quarter ended June 30, 2016.Vanda Pharmaceuticals'  CEO Mihael Polymeropoulos on Q2 2016 Results ... - Seeking Alpha"
p6
aS"Vanda Pharmaceuticals Announces the Appointment of European General Manager PR Newswire  - Sep 8, 2015 8, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc.   today announced that it has named Gian Piero Reverberi as Vanda's Senior Vice President, European General Manager."
p7
aS"Kenneth Bate Joins the Board of Directors of Vanda Pharmaceuticals PR Newswire  - Dec 18, 2015 WASHINGTON, Dec. 18, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc.  , announced today that Kenneth Bate, an independent biotechnology industry consultant, has joined Vanda's Board of Directors."
p8
aS'Vanda Pharmaceuticals Announces Participation at March 2017 Investor Conferences PR Newswire  - Mar 6, 2017 WASHINGTON, March 6, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc.   today announced that it will participate at the following upcoming investor conferences in March 2017.'
p9
aS'Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2015 ... PR Newswire  - Jan 11, 2016 WASHINGTON, Jan. 11, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc.  , a biopharmaceutical company focused on the development and commercialization of novel therapies addressing high unmet medical needs, today&nbsp;...'
p10
a.